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Modulation of antibody-mediated glomerular injury in vivo by IL-ira,
soluble IL-i receptor, and soluble TNF receptor. The severity of glomer-
ular injury in the heterologous phase of NTN is dependent on proinflam-
matory cytokines including TNFa and IL-1j3, and can be enhanced by
LPS. We have previously shown that passive immunization against IL-113
and TNF partialy abrogated the LPS effect in this model. In the present
work, we have assessed the effects on glomerular injury of blocking the
binding of IL-i to its receptor by rh IL-i receptor antagonist (IL-ira) and
by neutralizing IL-i and TNF with rm soluble IL-I receptor typel
(sIL-I Rtl) and rh sTNF receptor (sTNFr p55), respectively. Pretreatment
with either IL-ira, sIL-iRti, or sTNFr partially abrogated the effects of
LPS and reduced albumin excretion from 45 8, 66 9, and 101 17
mg124 hr to 13 4 (P < 0.02), 14 4 (P < 0.001), and 21 7 mg124 hr(P < 0.001), respectively. Similarly, these inhibitors reduced the preva-
lence of glomerular capillary thrombi and the intensity of glomerular
neutrophil infiltration. Glomerular thrombosis was reduced from 18
3%, 28 5%, and 25 7% to 3 2% (P < 0.002), 6 2% (P < 0.001),
and 3 2 (P < 0.001), respectively, and glomerular neutrophil infiltration
was reduced from 46 3, 54 2, and 59 8 to 19 2 (P < 0.001), 25
2 (P < 0.001), and 28 2 neutrophils/50 glomeruli in section,
respectively. Coadministration of both soluble receptors of IL-i and TNF
caused a further decrease in glomerular injury. The protective effect was
also noticed at four hours after induction of nephritis, and even when
these inhibitors were administered after the LPS injection and at the same
time of induction of nephritis. All three treatments reduced circulating
TNF concentration (down to 20%, 34%, and 0%, respectively) but without
detectable glomerular TNF gene expression. Glomerular IL-113 mRNA
levels were also reduced by 41%, 53%, and 67%, respectively, when
assessed by densitometric analysis of Northern blots. In contrast, the
glomerular expression of IL-ira was not affected by its exogenous admin-
istration but was mildly reduced by sIL-iRti and sTNFr, which demon-
strates the potential role for host derived IL-ira as an endogenous
negative feedback mediator in the glomerulus. These results confirm the
direct involvement of IL-i and TNF in LPS-enhanced hNTN and demon-
strate the potency of these inhibitors in modulating injury even when
administered after LPS and at time of induction of nephritis. They were
more specific and effective than passive immunization with polyclonal
antibodies, and this demonstrates their potential usefulness in the man-
agement of nephritis.
Interleukin-1 (IL-i) and tumor necrosis factor-cs (TNF) are
proinfiammatory cytokines which have been shown to amplify
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inflammatory [1, 2] and immunological injury [3, 4]. Their biolog-
ical effects are mediated by binding to specific receptors which are
widely distributed. There are two different receptors for IL-i: an
80 kD (kDa) IL-I receptor type 1 (IL-iRti), originally identified
on T-lymphocytes and fibroblasts [51 but subsequently found on
most cell types, and a 60 kD interleukin-i receptor type 2
(IL-iRt2), found mainly on B-lymphocytes, monocytes/macro-
phages and neutrophils [61. The receptors differ structurally [7],
and while IL-ia and IL-1j3 bind with high affinity to IL-IRtI [5],
IL-la has relatively little affinity for IL-lRt2 [81. Recently, the
function of both receptors have been elucidated [9]: IL-iRti
mediates the biological effects of IL-i, whereas IL-lRt2 acts as a
"decoy" which binds IL-i but has no agonist activity. Soluble
extracellular truncated domains of both IL-i receptors are re-
leased from cell membranes and can bind and neutralize both
IL-la and IL-1/3. Soluble IL-i receptors (sIL-iRti and sIL-lRt2)
can be detected in biological fluids taken from patients with
various diseases [10], and neutralize IL-i both in vitro [10, 11] and
in vivo [12—14].
The effects of IL-i are also attenuated in vivo by a specific
inhibitor known as IL-i receptor antagonist (IL-ira). IL-ira is an
18 kD glycoprotein that has 19% identity with the amino acid
sequence of IL-la and 26% with that of IL-1/3 [15, 16]. It is
produced by monocytes/macrophages [17, 18] and polymorpho-
nuclear cells [19, 20], and is a competitive inhibitor of the active
IL-i receptor (Rtl), but it has no affinity for the "decoy" IL-lRt2
[17, 21]. Increased plasma concentrations of IL-ira have been
found in clinical experimental endotoxemia, where they exceed
levels of IL-1f3 by at least 80-fold [22], and its expression has been
detected in local and systemic experimental endotoxemia [23].
Recombinant human IL-ira blocks the IL-i [24] and LPS-induced
cytokine synthesis in vitro [25], and reduces the local [26, 271 and
systemic inflammatory effects of IL-i in vivo [28—30].
Tumor necrosis factor also binds to two types of receptors: TNF
receptor type I and TNF receptor type 2 which have molecular
weights of 55 (p55) and 75 (p'75) kD, respectively [31]. The p55 is
responsible for mediating most of TNF actions including cytotox-
icity, antiviral activity, and induction of mRNAs, whereas the
function of p75 is probably mainly related to lymphocytic prolif-
eration and maturation [32]. However, both receptors are necessary,
and act synergistically, for DNA fragmentation and differentiation
[33] and mediation of apoptosis via induction of distinct signal
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pathways [34]. Truncated fragments of the extracellular domains
of TNF receptors are released as soluble forms which are known
as sTNFr p55 and sTNFr p75 [31, 321. They are released from
activated macrophages in vitro [35], and shed from neutrophils in
vivo following LPS stimulation [36]. Increased concentrations of
both soluble receptors are detectable in serum and other biolog-
ical fluids taken from patients with acute bacterial sepsis, malaria,
acute and chronic hepatitis, and in chronic inflammatory diseases
such as rheumatoid arthritis and systemic lupus erythematosus
[37]. These inhibitors are believed to neutralize excess TNF and
thus may contribute to the control of the inflammatory response
to injury [31, 381.
Previously, we have shown that small doses of endotoxin
increase the severity of glomerular injury in the heterologous
phase of nephrotoxic nephritis in rats [3], and that passive
immunization against IL-i and TNF abrogates the LPS effect [39].
However, the antibodies used in those experiments were poly-
clonal antisera and could have had additional nonspecific effects.
In the present work, we have examined whether natural inhibitors
of IL-i and TNF (IL-Ira, sIL-iRti, and sTNFr p55) are similarly
effective and whether the combined use of sIL-iRti and sTNFr
p55 is even more effective. We have also analyzed the mechanisms
involved by studying the changes in the endogenous cytokine
synthesis. The data confirm the direct involvement of IL-i and
TNF in mediating the LPS effects in this model of nephritis, and
demonstrate the effectiveness of these cytokine inhibitors in
controlling acute glomerular inflammation.
Methods
Animals
Male Sprague-Dawley rats weighing 180 to 200 g were used in
all the experiments. They were housed individually in metabolism
cages for 24-hour urine collections with free access to food and
water.
Reagents
Rabbit serum containing high titers of antibody to rat GBM was
prepared as described previously [40]. Immunoglobulin G (IgG)
was purified from the nephrotoxic serum using a Staphylococcus
protein-A column [41], with special care to avoid contamination
with endotoxin. The resulting IgG (anti-GBM Ab, nephrotoxic
antibody, NTAb) was tested for contamination with LPS by the
Limulus Amoebocyte Lysate assay, and the final concentration was
always less than 50 pg of LPS per ml of NTAb. A stock solution
of 2.5 mg/ml of LPS (Salmonella lyphimurium; Sigma Chemical
Co., St. Louis, MO, USA) was prepared and stored at 4°C until
required. Recombinant human IL-Ira was prepared at the MRC
Immunochemistry Unit (Oxford, UK) [16]. Recombinant murine
sIL-iRti was prepared at Behringwerke AG (Research United
Laboratories, Marburg, Germany); the plasmid pGEMBL-muIL-
1R-78 ext containing the entire coding sequence of the extracel-
lular region of the murine IL-i receptor type 1 [11] was obtained
from Immunex. The truncated IL-I receptor cDNA was excised
with Hindill and NotI and cloned into the corresponding sites of
the mammalian expression vector pCDM8 [42]. BHK-21 cells
expressing the soluble IL-i receptor were generated using an
efficient double selection protocol [43]. Clones producing 1 to 3
p.g/ml of IL-i receptor as measured by an IL-1R specific ELISA
were chosen for production in roller bottles. Conditioned super-
natants were purified following standard procedures on an immu-
noaffinity column consisting of the anti-murine IL-i receptor
monoclonal antibody Ml (Immunex) coupled to CNBr-activated
sepharose. The sTNFr p55 was prepared at Centocor, Inc. (PA,
USA) by fusion of the extracellular domain of human p55 TNF
receptor to the J sequence and constant domains of human IgGi,
which has a high affinity and neutralizing capacity towards human
and rat TNFa and TNF/3 [44]. These inhibitors were free from
contamination with endotoxin. The cDNA probes for rat IL-lp
and mouse TNFn, which cross reacts with rat TNFa [45], were
provided by Dr. Alan Shaw (Biogen, Geneva, Switzerland) and
the cDNA probe for rat IL-ira was prepared locally by PCR
technique [46]. The cDNA probe for human tubulin kal is a 1.6 kb
insert subcloned into pSP64 plasmid which was used as a control
to cross hybridize to rat mRNA [47].
Induction of nephrotoxic nephritis
Nephritis was induced by a single intravenous injection of 10 mg
of NTAb (nephrotoxic antibody) in 1 ml of phosphate buffered
saline (PBS). From previous experiments this dose was known to
cause minimal proteinuria in normal rats and severe nephritis in
rats pretreated with an intraperitoneal injection of 0.25 p.g of LPS
one hour previously. The severity of nephritis was assessed by
urinary albumin excretion, the percentage of glomeruli with
capillary thrombi (with at least one thrombus per glomerulus),
and by the number of neutrophils infiltrating glomeruli using
previously described methods [3, 39]. The assessment of these
determinations was performed at 4 and 24 hours after the
administration of NTAb.
Northern blot
In these studies, the kidneys were removed from rats killed at
four hours after induction of nephritis. Northern blot analysis was
performed as previously described [45, 46]. Briefly, kidney tissue
was collected for mRNA studies after the lower pole of the left
kidney was removed for histology while the rats were under ether
anaesthesia. Before removal, the kidneys were perfused in vivo
with 50 ml of PBS at room temperature followed by 10 ml of ice
cold PBS. Glomeruli were purified from the rest of the renal
tissues by standard sieving technique (250 p., 150 p., 63 p.) with ice
cold PBS. Purified glomeruli were immediately homogenized
(Ika-ultra-Turbax T25 Janke and Kunkal at 24000 rpm) in 4 M
guanidinium thiocyanate solution. Total RNA was purified from
the homogenate using the caesium chloride gradient ultracentrif-
ugation method [48]. Equal amounts of total glomerular RNA
were electrophoresed on a 3.2% formaldehyde, 1X MOP, 1%
agarose gel and transferred to GeneScreen plus TM (New England
Nuclear, Boston, MA, USA), by capillary blot using 10 X SSC
solution (1 X SSC = 15 mrvt trisodium citrate, 150 m sodium
chloride). Filters were pre-hybridized in 50% formamide, 1%
SDS, 10% dextran sulphate, 1 M NaC1 and 200 p.g!ml denatured
salmon testes DNA (Sigma) overnight at 42°C. Complementary
DNA probes were radiolabeled with 32P-CTP with Klenow DNA
polymerase (Sambrook, Fritsch, Maniatis). Filters were hybrid-
ized in the same pre-hybridization buffer at 42°C with radiola-
beled probe overnight. They were washed twice in 1% SDS + 1 X
SSC solution at 42°C for 30 minutes, and twice in 1% SDS + 0.1
>< SSC solution for another 30 minutes at the same temperature.
Some filters were washed further in 1% SDS + 0.01-0.1 X SSC
solution to reduce background radioactivity. Washed filters were
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Table 1. Pretreatment effect of IL-ira, sIL-irti, and sTNFr on severity of glomerular injury in the heterologous phase of nephrotoxic nephritis
Neutrophils/50
Treatment N
Albuminuria
mg/24 hr
N
Hematuria % GCT
Pulmonary
hemorrhage
glorneruli in
Section
Alpha 2-rn
p.g/ml
NTAb
LPS + NTAb
IL-Ira + LPS + NTAb
6
10
10
2 1
45 8 a
13 4
None
3
None
0 0
18
3 2 1
None
None
None
20 3
46 31b19 21
1643 168
6763 680
8253 750
1 b
j
NTAb
LPS + NTAb
sIL-iRti + LPS + NTAb
6
10
10
1 0.2
66 9 h
14 4
None
3
None
0 0
28 b6 2
None
None
None
24 2
25 21
1894 94
6342 788
6900 1133
1 h
j
NTAb 2 2 1 None 0 0 None 20 2 1270 200 b
LPS + NTAb
sTNFr + LPS + NTAb
5
5
101 17
21 7 1
None
None
25 1 b3 2 j NoneNone
59 8
28 2 1
5860 732
5860 554
Plasma concentration of alpha 2-macroglobulin (a2-M) at the start of the experiment was 247 6 rg/ml (N = 24). It increased following induction
of nephritis and preinjection of LPS caused a further significant increase, however, there was no statistical difference between these or pretreated groups.
Abbreviations are: %GCT, percentage of glomeruli with capillary thrombosis; NTAb, nephrotoxic antibody; LPS, bacterial lipopolysaccharide; N,
number of rats in each group; IL-Ira, interleukin-1 receptor antagonist; sIL-IRtI, soluble interleukin-1 receptor type 1; sTNFr, soluble tumor necrosis
factor receptor p55.
"P < 0.02
P < 0.001
exposed to X-OMAT Kodak film with intensifier screen at room
temperature or —70°C for various durations up to 14 days.
Multiple exposure times were used to ensure optimally exposed
films were available for densitometry. Filters were stripped of
radioactivity by washing in boiling 0.1% SDS and 0.1 X SSC
solution before the next hybridization. Degree of hybridization
was assessed by densitometric scanning (Chromoscan 3, Joye
Loebl) of suitable autoradiographs. Any difference in RNA
loading in each lane was corrected by normalization to the tubulin
hybridization.
Measurement of serum TNF
Five hundred microliters of blood was drawn off at each time
point. Blood samples were transferred to endotoxin free tubes,
incubated for 20 minutes at 37°C for the blood to clot, then
centrifuged at 1500 rpm for 15 minutes. The serum was removed
and stored at —20°C until TNF was measured by WEHI 164 clone
13/2F2 bioassay [49].
Assessment of the hepatic acute phase response
The hepatic acute phase response was assessed functionally by
measurement of plasma alpha 2-macroglobulin (a2-M) concen-
tration as previously described [39].
Creatinine clearance
Plasma and urine were both assayed for creatinine concentra-
tions using a standard colorimetric assay (Beckman autoanalyzer),
which is specific for creatinine and subject to minimal interference
from endogenous noncreatinine chromogens [50], and endog-
enous creatinine clearance (Cr) was calculated for all rats.
Statistical analysis
The data are presented as means together with standard errors
(SE). The probabilities that differences between the groups are
significant were calculated using Wilcoxon rank-sum test.
Results
None of the treatments, either alone or in combination, caused
apparent clinical disturbance. Normal control rats or rats injected
with either IL-ira or soluble receptors to IL-i or TNF, without
NTAb, showed no functional or morphological changes within the
kidneys.
Pretreatment effect of IL-ira on LPS-amplified hNTN
Six rats were injected intravenously with 0.5 ml pyrogen-free
normal saline (NS), followed 30 minutes later by 1 ml NS
intraperitoneally, and one hour later by 10 mg NTAb intrave-
nously. Ten rats were given 0.5 ml NS, 0.25 jig (1 ml) LPS, and 10
mg NTAb using the same times and routes, and another ten rats
were similarly treated except that 500 jig IL-Ira was injected
intravenously before LPS and NTAb instead of NS. The results
are summarized in Table 1. Pretreatment with LPS caused the
expected increase in renal injury: three of the rats developed
hematuria, and mean albuminuria excretion was increased to 45
8 mg124 hr compared to 2 1 mg124 hr for rats treated with
NTAb alone (P < 0.001). The percentage of glomeruli with
capillary thrombi were also significantly higher (18 3% com-
pared to 0 0%, P < 0.001), as were the number of glomerular
neutrophils per 50 glomeruli in section (46 3 and 20 3, P <
0.001, respectively). Administration of IL-Ira partially abrogated
the LPS effect: none of the treated rats had hematuria and
albuminuria was significantly less (13 4 mg/24 hr, P < 0.02), as
was the incidence of glomerular capillary thrombi and the gb-
merular neutrophil infiltration (Table 1). Injection of NTAb and
LPS caused an acute phase response as judged by the a2-M
concentrations at 24 hours, which was not affected by administra-
tion of IL-Ira (Table 1). None of the treatments either alone or in
combination had any significant effect on the creatinine clearance
(Ccr) at 24 hours. The Cr at the start of the experiment was 0.45
0.02 mI/mm, which was not statistically different from those
values of other differently treated groups.
Pretreatment effect of sIL-iRti on LPS-amplified hNTN
A similar protocol was used to assess the effect of neutralizing
IL-i by pretreatment with 500 jig sIL-iRti, and the results
showed that it was also effective (Table 1). Pretreatment with LPS
again significantly increased injury: three rats had hematuria, and
there were significant increases in albuminuria, the percentage of
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Table 2. Effect of simultaneous pretreatment of sIL-iRti and sTNFr on LPS-enhanced glomerular injury, and the effect of either soluble receptor
when administered after LPS injection and at the same time of induction of nephritis on the degree of glomcrular injury in the heterologous phase
of nephrotoxic nephritis
Treatment N
Albuminuria GCT Neutrophils/50
mg/24 hr % glomeruli in section
NTAb 4 2±1 0±0 25±2
LPS/NTAb
sIL-iRti + sTNFr/LPS/NTAb
5
5
64 19 1
a
4 2 1
8 3 1a
0 0 1
55 2 1 a
22 11
NTAb 2 8±4 2±2 23±5
LPS/NTAb
LPS/sIL-lRtl + NTAb
5
5
171 201
71 231
a 46 5 1
8 21
a 60 3 1
24 4]
a
LPS/sTNFr + NTAb 5 54 14 9 5 25 4
Abbreviations are: %GCT, percentage of glomeruli with capillary thrombosis; NTAb, nephrotoxic antibody; LPS, bacterial lipopolysaccharide; N,
number of rats in each group; sIL-iRtI, soluble IL-i receptor type 1; sTNFr, soluble TNF receptor p55.
ap < 0.001
glomeruli with capillary thrombosis, and the number of glomeru-
lar neutrophils (Table 1). The pretreatment with sIL-iRti par-
tially abrogated the effect of LPS as none of the rats had
hematuria and albuminuria was reduced to 14 4 mgJ24 hr (P <
0.001), the incidence of glomerular capillary thrombosis was
reduced to 6 2% (P < 0.001), and the glomerular neutrophil
infiltration was also reduced to 25 2 neutrophils per 50
glomeruli in section (P < 0.001, Table 1). Administration of
sIL-iRti had no significant effect on either plasma concentration
of cs2-M or creatinine clearance.
Pretreatment effect of sTNFr on LPS-amplified hNTN
Initial results showed that pretreatment with 100 .tg sTNFr (N
= 5) caused a small, though not statistically significant, attenua-
tion of the effect of LPS preinjection. Albuminuria was reduced
from 78 26 to 51 13 mg/24 hr, the incidence of glomerular
capillary thrombosis was reduced from 20 8 to 11 7%, and the
glomerular neutrophil numbers were reduced from 43 9 to 33
5 neutrophils per 50 glomeruli in section. The experiment was
repeated using a higher dose of sTNFr. Pretreatment with 400 i.Lg
sTNFr was much more effective with significant reduction in
albuminuria, the incidence of glomerular capillary thrombosis,
and glomerular neutrophil infiltration (Table 1). Similarly, admin-
istration of sTNFr had no significant effect on either plasma
concentration of a2-M or creatinine clearance (Table 1).
Simultaneous administration of sIL-iRti and sTNFr before LPS
injection and induction of nephritis
In this experiment we examined the effect of simultaneous
pretreatment of sIL-iRti and sTNFr on the degree of LPS-
enhanced glomerular injury. Four rats were injected intravenously
with 0.5 ml pyrogen-free normal saline (NS), followed 30 minutes
later by 1 ml NS intraperitoneally, and one hour later by 10 mg
NTAb intravenously. Five rats were given 0.5 ml NS, 0.25 jg (1
ml) LPS, and 10 mg NTAb using the same times and routes, and
another five rats were similarly treated except that 500 ig
sIL-iRti and 400 ig sTNFr were injected intravenously before
LPS and NTAb instead of NS. The results are summarized in
Table 2. Pretreatment with LPS caused the expected increase in
renal injury: the mean albuminuria excretion was increased to 64
19 mg/24 hr compared to 2 1 mg124 hr for rats treated with
NTAb alone (P < 0.001). The percentage of glomeruli with
capillary thrombi were also significantly higher (8 3% compared
to 0 0%, P < 0.001), as were the number of glomerular
neutrophils per 50 glomeruli in section (55 2 and 25 2 (P <
0.001), respectively. Co-administration of sIL-iRti and sTNFr
largely abrogated the LPS effect: albuminuria was significantly less
(4 2 mg/24 hr, P < 0.02), as was the incidence of glomerular
capillary thrombi and the glomerular neutrophil infiltration (Ta-
ble 2). The simulataneous administration of both soluble recep-
tors reduced albuminuria by 94% compared with 70 to 80%
reduction achieved by pretreatment with either of the two soluble
receptors, and caused complete protection against the formation
of glomerular capillary thrombosis.
Administration of sIL-IRti and sTNFr after the LPS injection and
the same time of induction of nephritis
In this experiment we examined the effect of changing the
timing of the administration of the soluble receptors of IL-i and
TNF on the degree of glomerular injury after the LPS injection.
Three groups of rats (N = 5/group) were injected intraperitone-
ally with 0.25 .rg LPS and 30 minutes later nephritis was induced,
in all groups, by an intravenous injection of 10 mg NTAb. At the
same time of induction of nephritis, group 1 received an intrave-
nous injection of pyrogen-free normal saline, group 2 were treated
with 500 g sIL-iRti, and group 3 with 400 rg sTNFr. Both
soluble receptors reduced the glomerular injury even when ad-
ministered one hour after LPS (Table 2). Albuminuria was 171
20 mg/24 hr in the control rats not given soluble receptors, 71
23 mg/24 hr in those treated with sIL-iRti (P < 0.001), and 54
14 mg/24 hr in those given sTNFr (P < 0.001). There were
comparable reductions in the prevalence of glomerular capillary
thrombi (46 5%, 8 2%, and 9 5%, respectively, P < 0.001)
and glomerular neutrophil infiltration (60 3, 24 4, and 25
4 neutrophils/50 glomeruli in section, respectively, P < 0.001).
These data demonstrate the effectiveness of both soluble recep-
tors in reducing the severity of glomerular injury even when given
after the LPS injection and at the same time of induction of
nephritis.
Effect of IL-ira, sIL-iRti, and sTNFr on endogenous synthesis of
IL-1f3, IL -ira, and TNF
Separate groups of four rats were studied to assess the effect of
IL-ira, sIL-iRti, and sTNFr pretreatment on systemic TNF
concentration and on glomerular expression of TNF, IL-1, and
IL-ira genes four hours after induction of nephritis. This time
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Table 3. Comparison between the effects of IL-Ira, sIL-iRti, and sTNFr on glomerular injury, systemic TNF concentration, and glomerular
cytokine synthesis at 4 hr in LPS-amplified heterologous nephrotoxic nephritis
Treatment
Number
of rats
Time
hours
.
Neutrophils/50
glomeruli in
section
.% of glomeruli
with capillary
thrombosis
Systemic
Serum TNF
RU/mi
Glomerular mRNA
TNF IL-i/I
IL-I/I/IL-ira
IL-ira ratio
LPS + NTAb 4 4 220 14 45 14 580 60 0% 100% 100% 1.0
IL-ira + LPS + NTAb 4 4 121 30 2 1 101 41 0% 59% 100% 0.59
sIL-iRti + LPS + NTAb 4 4 136 16 1 1 179 82 0% 47% 68% 0.69
sTNFr + LPS + NTAb 4 4 116 11 1 1 <5 0% 33% 16% 2.07
Densitometric measurements of glomerular cytokine mRNA were expressed as % of LPS + NTAb group
point was chosen because we have previously shown that the
degree of glomerular capillary thrombosis and glomerular neu-
trophil infiltration is maximal, and rats pretreated with IL-Ira,
sIL-IRti, and sTNFr had significantly less injury (Table 3). As
expected from our previous experiments, TNF concentrations
could not be detected at the start of the experiment or in rats
given NTAb alone (less than 5 reference units/ml, RU/mI), but
substantially increased (580 60 RU/mI) in rats injected with LPS
one hour before induction of nephritis. Neutralization of TNF
with sTNFr caused a complete reduction in serum TNF concen-
tration (less than 5 RU/ml), whereas neutralization of IL-i with
either IL-ira or sIL-iRti caused a substantial reduction in serum
TNF concentration (101 41 RU/mI and 179 82 RU/ml, P <
0.001, respectively). A similar observation was noticed in the
glomerular expression of IL-I/I which was remarkably reduced
following neutralizing treatments of IL-i and TNF. Glomerular
expression of TNF was not detectable in either treated or control
groups. Pretreatment with IL-ira, sIL-iRti, and sTNFr markedly
reduced the degree of increased hybridization following LPS for
glomerular IL-i/I gene expression by 41%, 53%, and 67%,
respectively, when assessed by densitometric analysis of Northern
blots (Figs. 1 and 2). Thus, treatments that neutralize TNF can
reduce IL-I/I synthesis and likewise treatments that neutralize
IL-i can also reduce TNF concentration, indicating an endoge-
nous interrelationship between both cytokines. Glomerular
mRNA for IL-i/I and IL-ira were not found by Northern analysis
in glomeruli removed from normal rats but were easily detected
four hours after induction of nephritis. The glomerular expression
of IL-Ira was not affected by administration of IL-Ira but was less
in rats treated with the soluble receptors (Fig. 1, 2).
Effect of a single intraperitoneal injection of LPS on serum TNF
concentration
As a control group, four rats were injected intraperitoneally
with 0.25 jig LPS and blood samples were taken at different time
points for measurement of serum TNF concentration by a cell
cytotoxicity assay. TNF was not detectable in any of the rat sera
(less than 5 RU/ml) at the start of the experiment, but the
concentration had risen significantly to 315 167 RU/mI 30
minutes after the LPS injection. The concentration peaked at one
hour (3700 2100 RU/ml), and started to decline by 1.5 hours
(1150 710 RU/mI) reaching 450 254 RU/mI at two hours and
was not detectable at 4 or 24 hours (less than 5 RU/ml). Thus the
small dose of LPS used, caused a transient but definite increase in
circulating TNF concentration.
Fig. 1. Northern blot analysis of glomerular mRNA for IL-I /3 and IL-Ira.
Northern blot analysis of glomerular RNA showing the same blot sequen-
tially probed for IL-i/I, IL-ira and tubulin. Samples include glomerular
RNA from rats injected with NTAb, LPS/NTAb, IL-lra/LPS/NTAb and
sIL-lRtl/LPS/NTAb. Splenic RNA from rats injected with LPS was the
positive control for hybridization.
Discussion
Nephrotoxic nephritis has proved to be a particularly useful
model for studying acute glomerular inflammation, principally
because the kinetics of injury have been so well characterized. The
heterologous phase injury is neutrophil-dependent and peaks four
to six hours after administration of anti-GBM antibodies. Even
though is a direct result of binding of antibodies to the basement
membrane, the severity of the resultant injury is influenced by
agents that modulate the inflammatory response [3, 51]. Our
previous work has shown that pretreatment with LPS greatly
enhances injury [3, 39, 45], and that the LPS effect is attenuated by
passive immunization against either IL-I/I or TNFa which sug-
gests that it is mediated by these cytokines [39]. In these studies
polyclonal antibodies against IL-i/I or TNFa were used and found
to be effective in reducing the degree of nephritis. However, these
Glomeruli
I I
n
zz
++
.c (I) U)< o_
-JI— —J
a- + +(1)
-
÷ cc
U) < U) ,—
D_ I— o -J
-J z -J —
IL-113 -18S
-28 S
IL-ira
-18 S
Tubulin
-18 S
0
..•. .
Karkar Ct al: Modulation of nephritis 1743
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Fig. 2. Northern blot analysis of glomernlar rnRNA for IL -1 13 and IL-ira.
Northern blot analysis of glomerular RNA showing the same blot sequen-
tially probed for IL-113, IL-Ira and tubulin. Samples include glomerular
RNA from rats injected with NTAb, LPSINTAb, and sTNFr/LPS/NTAb.
Splenic RNA from rats injected with 0.25 and 100 .rg LPS were the
positive control for hybridization.
polyclonal antibodies could bind to other molecules and could be
less specific for either cytokine. Therefore, more specific inhibi-
tors were used in the present experiments to ascertain the
involvement of IL-113 and TNFa in this model of nephritis and to
compare the effect of different types of treatment on glomerular
injuty. The results show unequivocally that inhibition of either
cytokine by soluble forms of their specific receptors or blocking
IL-i receptors with its natural antagonist, IL-ira, also markedly
inhibit injury, and that blocking both pathways has even a greater
effect. These results with our previous findings of neutralization of
IL-ip and TNFa, by polyclonal antibodies, clearly implicate and
document the involvement of both cytokines in this model of
ncphritis.
It is notable that both soluble receptors were much more potent
at attenuating injury than passive immunization even though they,
like the antibodies, are presumed to work by complexing with
their respective cytokine to neutralize it. There are at least three
explanations for this: it could be due to differences in the doses
used; to the greater affinity of the soluble receptors for their
ligands; or possibly because the soluble receptors, which are
smaller than IgG molecules, had greater access to locally synthe-
sized cytokines [52—55]. Irregardless of the mechanism, the results
show that the soluble forms of both receptors are highly effective
anti-inflammatory agents especially when administered together.
These results are also consistent with experiments in which
soluble receptors for IL-i and TNF have been shown to suppress
inflammation. Administration of soluble IL-i receptor has been
shown to suppress the clinical severity in experimental autoim-
mune encephalomyelitis in rats, a model which can be exacerbated
by IL-i [13], and to increase allograft heart survival and reduce
lymph node swelling in mice [12]. Similarly, administration of
soluble TNF receptor protects from toxicity induced by adminis-
tration of exogenous TNF [37], from lethal injections of LPS [561,
and diminishes the effects of LPS on galactosamine treated mice
[38]. Furthermore, blocking IL-i receptors with IL-ira, in the
present study, has also been shown to reduce the intensity of
nephritis to the same degree achieved by the soluble receptors.
-18 s This is also consistent with other experiments which showed the
ability of IL-ira not only to attenuate the LPS- and IL-i-induced
local injury and neutrophil infiltration [26, 57], but also to
abrogate glomerular injury, leukocyte infiltration, and ICAM-1
-28 S expression in a similar experimental system [58]. Taken together,
the results provide a powerful evidence that endogenous release
of soluble receptors, sIL-IRti and sTNFrp55, and IL-ira can play
a pivotal role in modulating inflammation in vivo.
-18 S The results also demonstrate the capacity of IL-i and TNF
inhibitors to influence synthesis of pro-inflammatory cytokines
including those within the glomerulus. This is illustrated by the
effects of these treatments on serum TNF concentrations. Unsur-
-18 S prisingly, TNF was not detected in the circulation at any time after
injection of soluble TNFr p55, but inhibition of IL-i, by either
soluble IL-iRti or IL-ira, also reduced circulating TNF concen-
trations by 70 to 80%, presumably because IL-I stimulates
macrophages to synthesize TNF. This is consistent with other
experiments which showed the ability of IL-ira to reduce the
circulating concentrations of TNF and IL-1/3 [59]. The effects of
the treatments on local synthesis of IL-I and TNF is much more
difficult to ascertain. However, measurements of specific mRNA
provide indirect evidence that all three treatments substantially
reduced glomerular IL-i /3 synthesis. We have shown previously
that administration of interleukin-6 (IL-6), which inhibits synthe-
sis of pro-inflammatory cytokines by macrophages, has the same
effect on glomerular IL-1/3 mRNA [451. Thus, treatments that
block IL-i receptors, bind IL-I and TNF, or inhibit their synthesis
all have the same effect on glomerular injury and cytokine
synthesis.
The source of IL-i/3 mRNA in glomeruli is unclear. The time
course correlates with that of infiltrating neutrophils, but rat
mesangial cells [60, 611 and podocytes [55, 621 have both been
reported to make it. It is of interest that neither IL-Ira nor sIL-1R
had an appreciable effect on glomerular expression of IL-ira,
whereas sTNFr effectively reduced the expression of IL-1/3 and
the need for IL-ira, which suggests that the treatments altered the
balance between pro- and anti-inflammatory cytokines in the
glomerulus. This is analogous to the change in the balance of IL-I
to its receptor antagonist during the evolution of the autologous
phase of nephrotoxic nephritis [461, and we have previously
suggested that this may act locally as a negative feedback regula-
tor of inflammation. However, neither of these changes should be
taken as a proof that administered inhibitors reached sufficient
concentrations to affect the binding of locally synthesized IL-i or
TNF to its receptors in the glomerulus. It is also possible that the
inhibitors work by preventing LPS induced changes in plasma
TNF, rather than through inhibiting cytokines within the glomer-
ulus.
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There are no published data bearing on whether treatment with
soluble IL-i or TNF receptors are effective within the glomerulus,
but recent experiments in the autologous phase of nephrotoxic
nephritis, by Atkins and his colleagues, provided an evidence that
this may be the case. They showed that continuous infusions of
IL-ira, given by osmotic minipumps, significantly reduces protein-
uria, leukocyte infiltration, and crescent formation in this model
[631. Surprisingly, there was little effect on injury during the first
24 hours despite the high pharmacological doses of IL-Ira used,
the phase of injury that is most similar to the heterologous phase.
This is in apparent contradiction to our results. However, the
apparent paradox could be resolved: (i) by suggesting that the
ability of the soluble receptors and the receptor antagonist to
attenuate injury in our experiments was due to their influence on
circulating TNF (and IL-1J3) concentrations, and (ii) by the high
rates of glomerular IL-l/3 synthesis in the first 24 hours that were
too great to be controlled by exogenous IL-ira, especially at a
time when glomerular synthesis of IL-ira was relatively low [46].
Later in the time course, glomerular IL-1f3 synthesis is much lower
while that of IL-ira is greater [461, suggesting that less exogenous
antagonists would be required for neutralization.
Our data also emphasize the complex relation between IL-i,
TNF, and leukocyte infiltration because leukocytes are a major
source of both cytokines, which in turn stimulate cells to synthe-
size chemokines such as macrophage inflammatory protein-2
(MIP-2) [64] which is a chemoattractant for neutrophils in rats
[65, 66]; they also increase the expression of adhesion molecules
such as ICAM-1 [671. All three treatments reduce the glomerular
concentrations of mRNA for MIP-2, which could be responsible
for the reduced glomerular neutrophil infiltration. This is because
glomerular expression of MIP-2 correlates with glomerular neu-
trophil counts in both heterologous and autologous phases of
nephrotoxic nephritis [Tam, Karkar and Rees, unpublished data].
In conclusion, we have shown that treatments designed to
reduce the union of IL-i and TNF to their respective cellular
receptors is highly effective at attenuating the effects of LPS on
the heterologous phase of nephrotoxic nephritis.
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